Literature DB >> 8334437

N-acetylation phenotyping with sulfamethazine in an Iranian population.

S Sardaş1, B Lahijany, I Cok, A E Karakaya.   

Abstract

The acetylation polymorphism is one of the most common inherited variations in the biotransformation of drugs and chemicals. Its association with drug toxicity and increased risk of developing certain diseases and certain types of chemically induced cancers has made it one of the oldest and best studied examples of pharmacogenetic conditions. N-Acetylation of sulfamethazine was studied in 74 unrelated healthy Iranian volunteers. The frequency of slow acetylators, determined by using free and total plasma sulfamethazine concentrations, was 78.4%. The mean acetylation ratio was 19.48% for slow acetylators, and the frequency of the recessive allele controlling slow acetylation was found to be 0.88. This percentage is similar to that observed in various Arab countries and higher than that observed in Europeans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334437

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  3 in total

1.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.

Authors:  Etienne Patin; Luis B Barreiro; Pardis C Sabeti; Frédéric Austerlitz; Francesca Luca; Antti Sajantila; Doron M Behar; Ornella Semino; Anavaj Sakuntabhai; Nicole Guiso; Brigitte Gicquel; Ken McElreavey; Rosalind M Harding; Evelyne Heyer; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2006-01-13       Impact factor: 11.025

2.  Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals.

Authors:  Valery V Bakayev; Forozan Mohammadi; Moslem Bahadori; Mariam Sheikholslami; Arash Javeri; Mohammad R Masjedi; Ali A Velayati
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

3.  Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism.

Authors:  Mohammad Sistanizad; Ebrahim Azizi; Hosein Khalili; Mahboobeh Hajiabdolbaghi; Kheirollah Gholami; Reza Mahjub
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.